false
--09-30
0001649989
0001649989
2024-03-07
2024-03-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): March 7, 2024
Outlook Therapeutics,
Inc.
(Exact name of registrant as specified in its charter)
Delaware |
001-37759 |
38-3982704 |
(State or other jurisdiction
of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
485 Route 1 South
Building F, Suite 320
Iselin, New Jersey |
08830 |
(Address of principal executive offices) |
(Zip Code) |
Registrant's telephone number, including area code:
(609) 619-3990
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on Which
Registered |
Common Stock |
|
OTLK |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 5.03 | Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year |
At the 2024 Annual Meeting of Stockholders (the “Annual Meeting”),
the stockholders of Outlook Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated
Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 425,000,000 to 1,200,000,000
shares. The increase in the authorized number of shares of the Company’s common stock was effected pursuant to a Certificate of
Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary
of State of the State of Delaware on March 7, 2024 and was effective as of such date. The foregoing description is qualified in its entirety
by the Certificate of Amendment, which is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 5.07 | Submission of Matters to a Vote of Security Holders |
At the Annual Meeting held on March 7, 2024, the Company’s stockholders
voted on eight proposals, each of which is described in more detail in the Company’s proxy statement on Schedule 14A filed with
the Securities and Exchange Commission on February 8, 2024 (the “Proxy Statement”). Of the 260,257,517 shares of the Company’s
common stock outstanding as of the record date, 194,030,258 shares, or approximately 74.6%, were present or represented by proxy at the
Annual Meeting.
The following is a brief description of each matter voted upon and
the certified results, including the number of votes cast for and against each matter and, if applicable, the number of votes withheld,
abstentions and broker non-votes with respect to each such matter.
Proposal
1. Stockholders elected each of the following nominees to serve as Class II directors on the Company’s Board of Directors
(the “Board”) until the Company’s 2027 Annual Meeting of Stockholders or until his or her successor has been duly elected
and qualified. The voting results for such nominees were as follows:
Director Name | |
Votes For | | |
Votes Withheld | | |
Broker
Non- Votes | |
Gerd Auffarth, M.D. | |
| 122,406,604 | | |
| 7,573,738 | | |
| 64,049,916 | |
Julia A. Haller, M.D. | |
| 126,307,671 | | |
| 4,173,076 | | |
| 63,549,511 | |
Andong Huang | |
| 128,730,972 | | |
| 1,749,775 | | |
| 63,549,511 | |
Lawrence A. Kenyon | |
| 125,464,513 | | |
| 4,524,055 | | |
| 64,041,690 | |
Proposal
2. Stockholders approved the potential issuance in excess of 19.99% of the Company’s outstanding common stock in a private
placement of shares of common stock and accompanying warrants at less than the “minimum price” under Nasdaq Listing Rule 5635.
The voting results were as follows:
Votes For | | |
Votes Against | | |
Abstentions | | |
Broker Non- Votes | |
| 123,467,622 | | |
| 6,224,132 | | |
| 788,993 | | |
| 63,549,511 | |
Proposal
3. Stockholders approved the potential issuance in excess of 19.99% of the Company’s outstanding common stock upon the
conversion of an outstanding convertible note at less than the “minimum price” under Nasdaq Listing Rule 5635, if required
pursuant to the terms of the convertible note. The voting results were as follows:
Votes For | | |
Votes Against | | |
Abstentions | | |
Broker Non- Votes | |
| 123,394,516 | | |
| 6,301,788 | | |
| 784,443 | | |
| 63,549,511 | |
Proposal
4. Stockholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase
the total number of shares of its common stock authorized for issuance from 425,000,000 to 1,200,000,000 shares. The voting results were
as follows:
Votes For | | |
Votes Against | | |
Abstentions | | |
Broker Non- Votes | |
| 123,007,844 | | |
| 6,742,110 | | |
| 730,793 | | |
| 63,549,511 | |
Proposal
5. Stockholders did not approve the amendment of the Company’s Amended and Restated Certificate of Incorporation to reflect
new Delaware law provisions regarding officer exculpation. The voting results were as follows:
Votes For | | |
Votes Against | | |
Abstentions | | |
Broker Non- Votes | |
| 125,438,289 | | |
| 3,598,772 | | |
| 1,443,686 | | |
| 63,549,511 | |
Proposal
6. Stockholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to effect a
reverse stock split of common stock, and a reduction in the number of authorized shares of common stock, at a ratio of 1-for-10 to 1-for-30.
The voting results were as follows:
Votes For | | |
Votes Against | | |
Abstentions | | |
Broker Non- Votes |
|
| 174,074,763 | | |
| 15,567,247 | | |
| 4,388,248 | | |
|
N/A |
|
Proposal
7. Stockholders ratified the selection by the Audit Committee of the Board of KPMG LLP as the Company’s independent registered
public accounting firm for its fiscal year ending September 30, 2024. The voting results were as follows:
Votes For | | |
Votes Against | | |
Abstentions | | |
Broker Non- Votes |
|
| 188,948,425 | | |
| 3,717,708 | | |
| 1,364,124 | | |
|
N/A |
|
Proposal
8. Stockholders approved a non-binding advisory vote on the compensation of the Company’s named executive officers. The
voting results were as follows:
Votes For | | |
Votes Against | | |
Abstentions | | |
Broker Non- Votes | |
| 126,964,912 | | |
| 3,193,076 | | |
| 322,759 | | |
| 63,549,511 | |
Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Outlook Therapeutics, Inc. |
|
|
Date: March 7, 2024 |
By: |
/s/ Lawrence A. Kenyon |
|
|
Lawrence A. Kenyon |
|
|
Chief Financial Officer |
Exhibit 3.1
CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF
INCORPORATION OF OUTLOOK THERAPEUTICS, INC.
Outlook Therapeutics,
Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies
that:
First: The name of the Company is Outlook Therapeutics,
Inc. (the “Company”).
Second:
The date of the filing the original Certificate of Incorporation of this Company with the Secretary of State of the State of Delaware
was October 22, 2015 and the date of filing of the Amended and Restated Certificate of Incorporation of the Company with the Secretary
of State of the State of Delaware was May 18, 2016.
Third: Paragraph
A of ARTICLE IV of the Company’s Amended and Restated Certificate of Incorporation be, and it hereby is, amended and restated to
read in its entirety as follows:
“A.
The Company is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred
Stock.” The total number of shares which the Company is authorized to issue is one billion two hundred and ten million (1,210,000,000)
shares. One billion two hundred million (1,200,000,000) shares shall be Common Stock, each having a par value of one cent ($0.01). Ten
million (10,000,000) shares shall be Preferred Stock, each having a par value of one cent ($0.01).”
Fourth: The
foregoing amendment was submitted to the stockholders of the Company for their approval, and was duly adopted in accordance with the provisions
of Section 242 of the General Corporation Law of the State of Delaware.
In Witness
Whereof, Outlook Therapeutics, Inc. has caused this Certificate of Amendment to be signed by its Chief Financial Officer, Treasurer
and Secretary this 7th day of March, 2024.
|
Outlook
Therapeutics, Inc. |
|
|
|
|
|
By: |
/s/
Lawrence A. Kenyon |
|
|
Lawrence
A Kenyon |
|
|
Chief
Financial Officer, Treasurer and Secretary |
v3.24.0.1
Cover
|
Mar. 07, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Mar. 07, 2024
|
Current Fiscal Year End Date |
--09-30
|
Entity File Number |
001-37759
|
Entity Registrant Name |
Outlook Therapeutics,
Inc.
|
Entity Central Index Key |
0001649989
|
Entity Tax Identification Number |
38-3982704
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
485 Route 1 South
|
Entity Address, Address Line Two |
Building F
|
Entity Address, Address Line Three |
Suite 320
|
Entity Address, City or Town |
Iselin
|
Entity Address, State or Province |
NJ
|
Entity Address, Postal Zip Code |
08830
|
City Area Code |
609
|
Local Phone Number |
619-3990
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock
|
Trading Symbol |
OTLK
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 3 such as an Office Park
+ References
+ Details
Name: |
dei_EntityAddressAddressLine3 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Apr 2024 to May 2024
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From May 2023 to May 2024